Full Press Release Details
Monogram Technologies Issues Correction to Press
Release Announcing it Received an FDA Response for its mB s TKA System (Correction Notice)
Company Has 180 Days From Receipt to Produce
Additional Information
AUSTIN, TX - October 3, 2024 -
Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused
on improving human health with an initial focus on orthopedic surgery, today announced a correction to its press release issued on Wednesday,
October 2, 2024, entitled "Monogram Technologies Receives FDA Response for mB s TKA System" (the "Prior Press
In yesterday's prior press release, dated
October 2, 2024, it was stated in the subtitle that: "Company to Conduct Clinical Trial to Produce Additional Information Within
180 Days." The Company now clarifies the subtitle should state: "Company Has 180 Days From Receipt to Produce Additional Information."
Other than this correction, there are no other changes to the previous press release.
About Monogram Technologies Inc.
Monogram Technologies (NASDAQ: MGRM) is an AI-driven
robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution
architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation
Monograms mB s precision robotic surgical
system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants.
The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical
equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation
necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mB s with mVision
navigation are also being explored.
Monogram has obtained FDA clearance for mPress
implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market
its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.
The Company believes that its mB s
precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee
implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates
that there may be other clinical and commercial applications for its navigated mB s precision robot and mVision
To learn more, visit monogramtechnologies.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical
facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results
and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds
is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected
by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the
Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance.
Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors,
including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any
forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
Executive Vice President
Direct: 949-491-8235